Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.

PubWeight™: 1.14‹?› | Rank: Top 10%

🔗 View Article (PMID 17709500)

Published in J Immunol on September 01, 2007

Authors

W Scott Webster1, R Houston Thompson, Kimberley J Harris, Xavier Frigola, Susan Kuntz, Brant A Inman, Haidong Dong

Author Affiliations

1: Department of Urology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

Articles citing this

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98

FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008) 1.63

STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18

PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res (2015) 1.14

The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09

Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol (2009) 1.09

TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol (2009) 1.08

Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood (2010) 1.03

Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93

B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. J Immunol (2010) 0.92

Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92

PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer (2016) 0.88

CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. J Immunol (2015) 0.80

ProtEx technology for the generation of novel therapeutic cancer vaccines. Exp Mol Pathol (2009) 0.79

Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy (2009) 0.77

CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma. Sci Rep (2016) 0.75

Human Renal Normal, Tumoral, and Cancer Stem Cells Express Membrane-Bound Interleukin-15 Isoforms Displaying Different Functions. Neoplasia (2015) 0.75

Articles by these authors

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96

Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23

The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11

Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08

Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73

Thromboembolism and bleeding in bladder cancer. Oncology (Williston Park) (2014) 2.66

Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66

Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. J Urol (2010) 2.53

Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52

Bladder cancer. J Natl Compr Canc Netw (2013) 2.46

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37

Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res (2007) 2.26

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24

The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19

B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19

B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood (2002) 2.17

Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14

Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol (2007) 2.12

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00

Urachal anomalies: a longitudinal study of urachal remnants in children and adults. J Urol (2007) 1.99

Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97

Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91

The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90

Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int (2012) 1.87

Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol (2008) 1.83

Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? BJU Int (2008) 1.79

B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol (2004) 1.78

MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol (2009) 1.76

Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75

Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. Eur Urol (2011) 1.74

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74

Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71

Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer (2005) 1.71

Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol (2008) 1.60

Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res (2007) 1.59

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int (2013) 1.59

Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol (2011) 1.57

Hyperthermia as a treatment for bladder cancer. Oncology (Williston Park) (2010) 1.56

Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol (2012) 1.53

Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol (2012) 1.53

Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol (2011) 1.45

Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int (2014) 1.45

Percutaneous cryoablation of solitary sporadic renal cell carcinomas. BJU Int (2012) 1.44

Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer (2005) 1.43

Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol (2005) 1.42

Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer (2006) 1.40

Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. BJU Int (2011) 1.40

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol (2007) 1.39

Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res (2011) 1.38

Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. Can Urol Assoc J (2009) 1.38

Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics (2010) 1.36

Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU Int (2010) 1.32

Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res (2007) 1.30

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28

Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer (2006) 1.26

Urinary fistulae after partial nephrectomy. BJU Int (2010) 1.22

Retracted Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J Immunol (2003) 1.21

Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol (2013) 1.21

The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol (2012) 1.19

Costimulation, coinhibition and cancer. Curr Cancer Drug Targets (2007) 1.15

Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int (2009) 1.13

Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology (2011) 1.11

Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res (2005) 1.10

Interpreting a study on bladder cancer screening. Eur Urol (2013) 1.08

TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol (2009) 1.08

Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer (2007) 1.07

ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol (2012) 1.07

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol (2014) 1.07

Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag Sci (2012) 1.06

A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int (2014) 1.06

TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol (2012) 1.05

B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology (2005) 1.03

Outcomes of metallic stents for malignant ureteral obstruction. J Urol (2012) 1.02

Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. J Infect Dis (2010) 1.01

Kidney function after partial nephrectomy: current thinking. Curr Opin Urol (2013) 1.00

Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. BMC Cancer (2010) 1.00

Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. J Immunol (2008) 1.00